证券代码：605369 证券简称：拱东医疗 公告编号：2023-014 浙江拱东医疗器械股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 浙江拱东医疗器械股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 05 月 10 日下午 16:00- 17:00 举行 2022 年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成 果、财务指标及现金分红的具体情况与投资者进行互动交流和沟通，在信息披 露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 05 月 10 日下午 16:00-17:00 会议召开时间：2023 年 05 月 10 日（星期三）下 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 226.19 million, a decrease of 34.96% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 28.91 million, down 69.58% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 23.39 million, a decline of 74.75% compared to the previous year[5]. - Basic and diluted earnings per share were both CNY 0.26, reflecting a drop of 69.49%[6]. - Total operating revenue for Q1 2023 was ¥226,188,708.14, a decrease of 34.9% compared to ¥347,749,231.30 in Q1 2022[26]. - Net profit for Q1 2023 was ¥28,912,951.01, a decline of 69.6% from ¥95,054,252.06 in Q1 2022[27]. - Basic and diluted earnings per share for Q1 2023 were both ¥0.26, compared to ¥0.84 in Q1 2022[28]. - Other comprehensive income for Q1 2023 showed a loss of ¥3,395,572.09, compared to a loss of ¥57,908.67 in Q1 2022[27]. Cash Flow and Assets - The net cash flow from operating activities was CNY 37.98 million, a decrease of 27.49% year-on-year[6]. - The company's cash and cash equivalents decreased to RMB 473,557,383.16 from RMB 753,233,997.85, a reduction of approximately 37%[23]. - The cash inflow from financing activities was CNY 990,795.00, compared to CNY 661,888.80 in Q1 2022[31]. - The net cash flow from financing activities was -CNY 328,906.20, a decline from CNY 661,888.80 in the previous year[31]. - The company reported a significant decrease in cash received from sales, totaling CNY 247,885,817.43, down 38.0% from CNY 401,122,062.90 in Q1 2022[30]. - The cash outflow for purchasing goods and services was CNY 108,233,245.15, a decrease of 59.0% compared to CNY 264,283,238.89 in Q1 2022[30]. - The total cash outflow from investing activities was CNY 311,844,895.84, an increase of 62.0% compared to CNY 192,607,539.73 in Q1 2022[31]. - The net cash flow from investing activities was -CNY 311,837,895.84, worsening from -CNY 81,691,339.33 in Q1 2022[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,817.47 million, down 2.68% from the end of the previous year[6]. - Total liabilities as of Q1 2023 amounted to ¥197,881,246.94, down from ¥275,298,695.27 in the previous year[26]. - The equity attributable to shareholders increased by 1.72% to CNY 1,619.59 million[6]. - The company's total assets as of March 31, 2023, amounted to RMB 1,817,470,290.79, down from RMB 1,867,488,228.30 at the end of 2022, indicating a decrease of about 2.5%[24]. - Accounts receivable as of March 31, 2023, were RMB 208,133,668.02, down from RMB 238,627,427.15, reflecting a decrease of about 13%[23]. - The company's fixed assets increased to RMB 641,870,702.76 from RMB 581,351,200.34, representing an increase of about 10.4%[24]. - The company’s accounts payable decreased to RMB 89,504,424.06 from RMB 147,606,805.21, a decline of approximately 39%[24]. Strategic Developments - The decline in revenue was attributed to factors such as extensive holidays in January, high sales base from the previous year, and inventory reduction by downstream customers[9]. - The company completed a capital increase of USD 45 million for its wholly-owned subsidiary GD Medical, primarily for the acquisition of core assets from TPI[15]. - GD Medical was renamed Trademark Plastics Inc. following the completion of the asset acquisition[20]. - Research and development expenses for Q1 2023 were ¥16,291,868.49, up from ¥13,734,416.42 in Q1 2022, indicating a focus on innovation[27]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[29].

Financial Performance - The company's operating revenue for 2022 was CNY 146,868.45 million, representing a year-on-year increase of 22.98% compared to CNY 119,425.42 million in 2021[26]. - The net profit attributable to shareholders for 2022 was CNY 32,604.82 million, a 4.84% increase from CNY 31,098.72 million in 2021[26]. - The net cash flow from operating activities decreased by 24.19% to CNY 28,275.27 million in 2022, down from CNY 37,298.62 million in 2021[26]. - The total assets at the end of 2022 were CNY 186,748.82 million, reflecting a 10.51% increase from CNY 168,991.12 million at the end of 2021[26]. - The basic earnings per share for 2022 were CNY 2.91, up 5.05% from CNY 2.77 in 2021[28]. - The weighted average return on equity for 2022 was 22.09%, a decrease of 2.57 percentage points from 24.66% in 2021[28]. - The company reported a net profit of CNY 9,505.43 million in Q1 2022, with a total operating revenue of CNY 34,774.92 million for the same quarter[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for 2022 was CNY 32,226.35 million, an increase of 8.85% from CNY 29,606.83 million in 2021[26]. - The company's net assets attributable to shareholders at the end of 2022 were CNY 159,218.95 million, a 14.71% increase from CNY 138,803.40 million at the end of 2021[26]. - The total revenue for 2022 was CNY 145,943.78 million, representing a year-on-year increase of 22.81% compared to CNY 118,840.87 million in 2021[77]. Dividend Distribution - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares, totaling 33,788,136.00 RMB, which accounts for 10.36% of the net profit attributable to shareholders[6]. - The company has a cash dividend policy that mandates a minimum of 10% of the distributable profit to be distributed as cash dividends annually[200]. - The company plans to distribute dividends in cash or other legally permitted methods, depending on the financial health and operational needs[200]. - The company will adjust its dividend distribution based on rapid revenue growth and stock price evaluations[200]. Research and Development - The company invested CNY 72.35 million in R&D, accounting for 4.93% of operating revenue, with a 24.11% increase in R&D spending compared to the previous year[39]. - The company has ongoing R&D projects focusing on customized products, basic material research, and high-capacity, high-precision mold manufacturing processes[104]. - The company holds 68 domestic authorized patents, including 5 invention patents, with 20 new patents granted during the reporting period[103]. - The company is focused on technological innovation, with multiple proprietary technologies developed for disposable medical consumables[66]. - The company aims to increase R&D investment to enhance core competitiveness and accelerate the development of key technologies[154]. Market and Sales Performance - The company’s direct material costs for medical devices were CNY 60,628.68 million, accounting for 68.54% of total costs, which is a decrease from 70.42% in the previous year[88]. - Domestic sales accounted for CNY 102,283.56 million, which is 70.08% of total revenue, showing a 32.78% increase from CNY 77,034.96 million in 2021[78]. - The revenue from virus sampling tubes and related products reached 248.13 million RMB, significantly up from 104.97 million RMB in 2021[72]. - The overseas sales revenue was CNY 43,660.23 million, a 4.44% increase from CNY 41,805.91 million in 2021, with OEM/ODM sales making up 88.68% of this segment[82]. - The company’s medical consumables and packaging products saw a production increase of 14.69%, totaling 17,390.84 tons, with sales volume rising by 21.29% to 17,640.18 tons[85]. Strategic Focus and Future Plans - The company’s strategic focus includes expanding IVD supporting business and customized products in the pharmaceutical sector[40]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[85]. - The company aims to enhance market expansion by strengthening domestic and international dual circulation, focusing on customer cooperation and developing new markets, particularly in South China and Northwest regions[156]. - The company is focusing on diversifying its operations while strengthening its core business, utilizing capital market resources for investments and mergers to enhance overall strength[158]. - The company plans to deepen standardized operations and improve governance effectiveness, ensuring compliance and risk management[152]. Governance and Management - The company has confirmed that all board members can guarantee the authenticity, accuracy, and completeness of the annual report[9]. - The company held its annual general meeting on May 10, 2022, where 13 proposals were approved, including the three-year shareholder return plan for 2022-2024[171]. - The financial director position was transitioned from Jiang Xixi to Pan Lei on April 15, 2022[173]. - The company has a structured remuneration policy for directors and senior management based on industry standards and internal management systems[181]. - The management team has extensive experience in the medical device industry, with key personnel having held various positions in related companies[178]. Risks and Challenges - The company faces risks from potential changes in industry regulations and policies that could impact market supply and demand, operational models, and pricing[160]. - Direct materials account for approximately 70% of the company's main business costs, making it vulnerable to fluctuations in raw material prices influenced by global commodity prices[163]. - The company’s overseas sales reached 394.39 million yuan, accounting for 26.85% of total revenue, exposing it to exchange rate fluctuations that could impact profitability[164]. Quality Control and Compliance - The company has established a comprehensive quality control system and has obtained ISO13485 certification, with several products certified by the EU CE and FDA 510(k) approvals[51]. - The production process adheres to ISO13485 quality management standards, with a customer demand-oriented "make-to-sell" production model[55]. - The company emphasizes compliance with its remuneration policies, ensuring that disclosed remuneration aligns with actual payments[181].

Financial Performance - The company's operating revenue for 2021 was CNY 119,425.42 million, representing a 43.95% increase compared to CNY 82,965.18 million in 2020[22]. - The net profit attributable to shareholders for 2021 was CNY 31,098.72 million, a 37.68% increase from CNY 22,588.10 million in 2020[22]. - The net cash flow from operating activities reached CNY 37,298.62 million, up 54.01% from CNY 24,218.25 million in 2020[22]. - The total assets at the end of 2021 were CNY 168,991.12 million, a 22.84% increase from CNY 137,567.83 million at the end of 2020[22]. - The basic earnings per share for 2021 was CNY 2.77, an increase of 11.24% compared to CNY 2.49 in 2020[24]. - The weighted average return on equity for 2021 was 24.66%, a decrease of 9.46 percentage points from 34.12% in 2020[24]. - The company achieved a revenue of 1,194.25 million RMB in 2021, representing a growth of 43.95% compared to the previous year[63]. - The net profit attributable to shareholders reached 310.99 million RMB, an increase of 37.68% year-on-year[63]. - The total assets amounted to 1,689.91 million RMB, with a debt total of 301.88 million RMB, resulting in an asset-liability ratio of 17.86%[63]. Dividend Distribution - The company plans to distribute a cash dividend of 13.80 RMB per 10 shares, totaling approximately 155.43 million RMB, which accounts for 49.98% of the net profit attributable to shareholders[6]. - The company’s total share capital is 112,627,120 shares as of the dividend distribution proposal date[6]. Audit and Compliance - The company reported a standard unqualified audit opinion from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[5]. - The company has not experienced any non-operational fund occupation by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures regarding external guarantees[8]. - The company emphasizes transparency in investor relations and adheres to strict information disclosure obligations[178]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[177]. - The company has not faced any significant legal or regulatory discrepancies in its governance practices[179]. Market and Sales Performance - Domestic sales revenue reached RMB 770.35 million, a significant increase of 85.30% compared to 2020[42]. - The overseas sales revenue was RMB 418.06 million, showing a modest growth of 3.54% year-on-year[42]. - The company’s main products include vacuum blood collection systems, laboratory testing consumables, and medical care consumables, which are widely used in clinical diagnostics and care[51]. - The marketing network covers over 100 countries and regions, with established partnerships with international clients such as McKesson and Thermo Fisher[58]. - The company’s investment activities saw an increase in cash outflow due to higher spending on financial products and fixed asset purchases[68]. Research and Development - Research and development expenses totaled RMB 58.29 million, accounting for 4.88% of the total revenue, with a year-on-year increase of 57.62%[40]. - The company obtained 11 new utility model patents and 1 design patent during the reporting period[40]. - The company has been recognized as a high-tech enterprise, emphasizing its commitment to research and technological innovation[51]. - The strategic focus for R&D includes the development of customized products and high-precision mold manufacturing processes to support future projects[110]. Operational Efficiency - The company has restructured its domestic sales operations into three independent departments: "Medical Business," "IVD Supporting Business," and "Pharmaceutical Business" to enhance management efficiency[43]. - The company employs a "make-to-order" production model to optimize inventory management and reduce storage costs[52]. - The company is currently operating at full capacity and will implement various measures to expand production capacity, including the construction of an intelligent factory[159]. - The company will improve its management system and organizational model to meet the growing demands of its expanding asset and production scale[161]. Risks and Challenges - The company has outlined potential risks in its future development, which investors should be aware of[9]. - Future fluctuations in raw material prices, influenced by global commodity prices, could adversely affect the company's operating performance if not managed properly[171]. - The implementation of centralized procurement policies may pose risks to the company, particularly if it cannot adapt to changes in the low-value medical consumables sector[169]. Governance and Management - The company has established specialized committees, including Audit, Nomination, Compensation and Assessment, and Strategic Decision Committees, to enhance governance[197]. - The company is committed to maintaining effective oversight of financial reporting and auditing processes through its committees[198]. - The company has a history of management changes, with several key personnel having extensive experience in the medical device industry[188]. - The company reported significant management stability, with many executives having long tenures in their respective roles[188]. Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22]. - The company aims to become a world-leading supplier of disposable medical consumables, focusing on high quality and efficiency[157]. - In 2022, the company plans to enhance production capacity and accelerate new product development, while exploring applications of polymer consumables in life sciences and veterinary fields[158]. - The company intends to utilize investment and acquisition strategies to seek global cooperation opportunities and optimize its industrial layout[166].

Financial Performance - Operating income reached CNY 26,203.50 million, a year-on-year increase of 155.93%[5] - Net profit attributable to shareholders was CNY 7,936.30 million, up 232.18% year-on-year[5] - The basic earnings per share increased by 147.50% to CNY 0.99[5] - The company's operating revenue for Q1 2021 reached RMB 26,203.50 million, a significant increase of 155.93% compared to RMB 10,238.41 million in the same period last year[15] - The company's profit before tax saw a substantial rise, leading to income tax expenses of RMB 1,294.30 million, up 408.21% from RMB 254.68 million in the previous year[16] - Operating profit for Q1 2021 was ¥92,407,444.53, up from ¥26,740,319.71 in Q1 2020, representing a growth of 245.5%[29] - Net profit for Q1 2021 was ¥79,363,027.05, compared to ¥23,891,296.23 in Q1 2020, marking an increase of 231.5%[30] - The total profit for Q1 2021 was ¥92,306,044.77, compared to ¥26,438,092.74 in Q1 2020, an increase of 249.5%[29] Cash Flow - Net cash flow from operating activities surged by 477.67% to CNY 7,496.84 million[5] - The net cash flow from operating activities for Q1 2021 was ¥74,968,444.93, up from ¥12,977,822.01 in Q1 2020, representing a growth of 478%[35] - The cash inflow from operating activities totaled ¥291,695,126.78 in Q1 2021, compared to ¥117,729,264.36 in Q1 2020, reflecting a growth of 147%[35] - The company reported a net increase in cash and cash equivalents of ¥30,515,315.59 in Q1 2021, contrasting with a decrease of -¥69,425,330.57 in Q1 2020[36] Assets and Liabilities - Total assets increased by 8.63% to CNY 149,436.63 million compared to the end of the previous year[5] - The total liabilities increased significantly, with contract liabilities rising by 91.38% to RMB 5,858.98 million due to increased sales[14] - Current liabilities rose to CNY 346,887,237.31, compared to CNY 163,324,507.84 in the previous period, indicating a significant increase of about 112.5%[21] - The total liabilities increased to CNY 350,964,243.26 from CNY 167,737,235.03, reflecting a growth of approximately 109.0%[21] - The total assets as of March 31, 2021, amounted to RMB 1,141,863,175.16, compared to RMB 1,047,376,755.51 at the end of 2020[19] Shareholder Information - The number of shareholders reached 11,843 at the end of the reporting period[11] - The top shareholder, Shi Huiyong, holds 52.50% of the shares, totaling 42,000,000 shares[11] Research and Development - The company's R&D expenses increased by 140.48% to RMB 1,109.84 million, indicating a focus on innovation and product development[15] - Research and development expenses in Q1 2021 amounted to ¥11,098,409.42, which is 140.5% higher than ¥4,615,119.03 in Q1 2020[31] Inventory and Accounts Receivable - Inventory rose by 44.67% to RMB 9,712.33 million, driven by the increase in sales volume[14] - Accounts receivable financing increased by 54.45% to RMB 1,443.87 million, attributed to increased sales and more bank acceptance bills received[14] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[13]